The glucagon receptor component activates meaningfully, increasing thermogenesis and metabolic rate
Pasireotide inhibits insulin secretion via SSTRs-Gi activation in GLP-1R-MIN-6 cells, and GLP-1 reverses the inhibitory action of pasiretoide on insulin secretion
CrossRef PrevotellaDerived Butyrate Inhibits CD8+ TCell Glycolysis via AKT/mTOR Signalling to Alleviate MASH Feixiang Xiong, Fengna Yan, Yuyong Jiang, Xiaomin Ji, Tong Wu, Yang Zhou, Xuejie Zhang, Dandan Chen, Yixin Hou Liver International .2026;[Epub] CrossRef CT-assessed abdominal visceral adiposity and MASLD: a sex-stratified cross-sectional analysis Linying Xu, Ting Chen, Yitian Xie, Xueyu Xiang, Yupeng Liu, Chongyong Xu, Shuran Wang Frontiers in Nutrition .2026;[Epub] CrossRef MetALD at the crossroads of metabolic and alcohol-related liver disease Gustavo Ayares, Luis Antonio Daz, Juan Pablo Arab, Marco Arrese Trends in Endocrinology & Metabolism .2026;[Epub] CrossRef Placebo-associated changes in MRI-PDFF and metabolic parameters in MASLD patients from phase Ib/IIa clinical trials: implications for early-phase trial design and translational endpoint interpretation Mengdi Lu, Hong Zhang, Xiaoxue Zhu, Jia Xu, Lin Xiang, Yue Hu, Jixuan Sun, Jiajia Mai, Yanhua Ding Frontiers in Pharmacology .2026;[Epub] CrossRef Aging-related skeletal muscle loss on the incidence of chronic kidney disease in patients with metabolic dysfunction-associated steatotic liver disease Aryoung Kim, Danbee Kang, Sung Chul Choi, Dong Hyun Sinn, Hye Ryoun Jang, Geum-Youn Gwak The Journal of nutrition, health and aging .2026
Some patients report chronic nausea and escalating severe pain that does not improve with standard treatment, leading to repeat ER visits or specialist referrals
A comparison of adding liraglutide versus a single daily dose of insulin aspart to insulin degludec in subjects with type 2 diabetes (BEGIN: VICTOZA ADD-ON)
The FDA's Pharmacy Compounding Advisory Committee has been slated for an upcoming discussion on whether certain peptides from compounding pharmacies should be cleared for use, signaling a potential reversal of a 2023 decision by the agency, as Fierce Pharma reports
